HIM
TXG icon

Hillsdale Investment Management’s 10x Genomics TXG Stock Holding History

Hillsdale Investment Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.29M Buy
+216,200
New +$5.67M 0.19% 139

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Hillsdale Investment Management's TXG Position: Q2 2026 in Review

Hillsdale Investment Management opened a new position in 10x Genomics (TXG) in Q2 2026: 216,200 shares worth $8.29M. The stake represents 0.19% of the portfolio and ranks #139 among its holdings.

390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Hillsdale Investment Management held 216,200 shares of 10x Genomics worth $8.29M as of Q2 2026.
  • 10x Genomics was a new Hillsdale Investment Management position in Q2 2026.
  • 10x Genomics made up 0.19% of Hillsdale Investment Management's portfolio in Q2 2026, its #139 holding.
  • 390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Hillsdale Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.